Ann Dermatol.  2016 Jun;28(3):409-411. 10.5021/ad.2016.28.3.409.

Exacerbation of Psoriasis after Imatinib Mesylate Treatment

• Shim JH
• Oh SH
• Jun JY
• Kim JH
• Park HY
• Park JH
• Lee DY

• KMID: 2164660
• DOI: http://doi.org/10.5021/ad.2016.28.3.409

Abstract

No abstract available.

MeSH Terms

Imatinib Mesylate*
Psoriasis*
Imatinib Mesylate

Figure

• 

  Fig. 1 (A) After two months of imatinib treatment, the patient developed painful symmetric erythema over palms and soles and desquamation with pain. (B) Exacerbation of guttate psoriasis on the buttocks after two months of imatinib treatment. (C) The patient also developed typical features of psoriatic nail dystrophy. (D) Improvement of skin lesions after six weeks of imatinib withdrawal and topical treatment.

• 

  Fig. 2 Histopathologic examination of a biopsy from the buttocks shows epidermal hyperkeratosis, loss of granular layer, regular acanthosis with parakeratosis, and microabscess (H&E, ×100).

Reference

1. Cho AY, Kim DH, Im M, Lee Y, Seo YJ, Lee JH. Pityriasis rosea-like drug eruption induced by imatinib mesylate (Gleevec(TM)). Ann Dermatol. 2011; 23:Suppl 3. S360–S363.

2. Woo SM, Huh CH, Park KC, Youn SW. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J Dermatol. 2007; 34:724–726.

3. Atalay F, Kızılkılıç E, Ada RS. Imatinib-induced psoriasis. Turk J Haematol. 2013; 30:216–218.

4. Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, et al. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL-tumors. J Immunol. 2008; 181:6955–6963.

5. Thachil J. T-regulatory cell response in psoriasis and changes with imatinib therapy. Clin Exp Dermatol. 2009; 34:e1022.